



## HERPES ZOSTER INCIDENCE IN PEOPLE WITH HIV: A RETROSPECTIVE COHORT STUDY




Nikita Stempniewicz<sup>1</sup>, Andrea Steffens<sup>2</sup>, Kimvi Kim<sup>1</sup>, Mary DuCharme<sup>2</sup>, Helen Trenz<sup>2</sup>, <u>Cindy P Garris<sup>3</sup></u>, David Singer<sup>1</sup>

<sup>1</sup>GSK, Philadelphia, PA, USA; <sup>2</sup> Optum, Eden Prairie, MN, USA; <sup>3</sup> ViiV Healthcare, Durham, NC, USA







## **CONCLUSIONS**

✓ HZ incidence was high among people with HIV and prioritization of HZ prevention may be warranted.

Further investigation is needed to understand differences in HZ incidence rates among people with HIV by baseline antiretroviral therapy, and similar HZ incidence across age, race, and ethnicity.

1. CDC.2021.https://www.cdc.gov/vaccines/pubs/pinkbook/herpes zoster.html(accessed8/24/2022).

2. JohnsonBHetal.JMedEcon.2016.19(10):928-35

Funding: GlaxoSmithKline Biologicals SA (GSK study identifier: VEO-000373). Acknowledgments: Business & Decision Life Sciences c/o GSK. Authors thank Felix Cao, Priyanka Koka, Carrie Song, Lynn Wacha, Meixia Liu, Christina Landis, Simi Khan (OPTUM) for their contribution during the conduct of the study.

\*cohorts were identified based on ICD-10 diagnosis codes